PLX Deferred Revenue
Protalix Biotherapeutics Inc · Deferred Revenue
PLX Deferred Revenue
Latest reported$0.00period ending
PLX Quarterly Deferred Revenue ($0.00 → $0.00)
Quarterly deferred revenue
High-resolution chart · PNG
PLX deferred revenue history
Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | Deferred Revenue (USD) |
|---|---|
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 2,000,000 | |
| 0 | |
| 0 | |
| 12,695,000 | |
| 11,039,000 | |
| 0 | |
| 0 | |
| 0 | |
| 11,790,000 | |
| 13,178,000 | |
| 0 | |
| 10,223,000 | |
| 11,801,000 | |
| 8,550,000 | |
| 15,160,000 | |
| 18,109,000 | |
| 2,560,000 | |
| 5,394,000 | |
| 0 | |
| 18,352,000 | |
| 19,014,000 | |
| 16,335,000 | |
| 11,612,000 | |
| 7,542,000 | |
| 9,429,000 | |
| 9,868,000 | |
| 61,780,000 | |
| 31,885,000 | |
| 29,030,000 | |
| 26,851,000 | |
| 0 | |
| 1,925,000 | |
| 1,925,000 | |
| 837,000 | |
| 504,000 | |
| 504,000 | |
| 504,000 | |
| 504,000 | |
| 6,850,000 | |
| 6,928,000 | |
| 7,072,000 | |
| 6,763,000 | |
| 6,620,000 | |
| 7,282,000 | |
| 7,609,000 | |
| 9,369,000 | |
| 9,513,000 | |
| 9,003,000 | |
| 8,591,000 | |
| 9,437,000 | |
| 4,564,000 | |
| 4,858,000 | |
| 4,858,000 | |
| 6,121,000 | |
| 5,633,000 | |
| 6,146,000 | |
| 4,563,000 | |
| 4,563,000 | |
| 4,563,000 | |
| 4,563,000 | |
| 4,563,000 | |
| 4,563,000 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 |